With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
Adrian Towse, Emeritus Director & Senior Research Fellow, Office of Health Economics
Prashant Yadav, Visiting Fellow, Center for Global Development
ABOUT THE EVENT
Spending on pharmaceuticals and other health care commodities is one of the fastest growing elements of healthcare spending in rich and poorer countries alike. A popular response to the problem of escalating drugs budgets has been seeking transparency of drug pricing within and across borders. In a rare alignment of policy priorities, the Trump administration, the US Senate, and the World Health Organization are calling for more transparency of the prices paid for prescription drugs as a means of reducing prices or (in WHO’s case) getting to “fair prices”. But is price transparency really an answer to healthcare systems’ fiscal sustainability challenges as they strive to expand access to new technologies or even merely sustain provision within strained public budgets? Will making prices publicly available make procurement more efficient, and make cost-effective medicines more accessible? In this seminar, Adrian Towse will discuss research on the role that price transparency may play in the efficient and effective procurement of medicines by low and middle-income countries.
Health systems around the world can suffer from a crisis of distrust; patients may question the quality of government clinics and newspapers may expose private hospitals for peddling unnecessary procedures. These are symptoms of volume-based health systems that focus on the quantity of care delivered rather than quality or outcomes. Many countries are accelerating down this path. Hospital construction sometimes surpasses growth of primary care infrastructure. New insurance schemes sometimes expand access to inpatient treatment, without equivalent expansion of community-based prevention. These approaches create lasting structural flaws which increase costs without delivering desired results. As countries commit to universal health coverage (UHC), there is a narrow window to chart a different trajectory toward the common goal of achieving the best health outcomes for the resources invested.
Please join us to discuss the new IDRC book Scaling Impact: Innovation for the Public Good. Co-authors, Robert McLean and John Gargani, will discuss the new and practical approach to scaling the positive impacts of research and innovation outlined in the book, based on a review of over 200 IDRC studies and 5 in-depth case explorations.
The digital transformation of the global economy can help businesses and governments provide services more efficiently and effectively. But it also creates new risks for individuals whose personal data may be used to improve products and services.
The Chinese government’s Belt and Road initiative, now entering its 7th year, has generated a great deal of attention globally. The visibility of the initiative reflects its priority among China’s senior leadership, the consideration of the initiative as both opportunity and risk among potential partner governments, and the concerns raised by its critics. The discourse to date has been dominated by political and strategic considerations. The economics of BRI has received considerably less attention, partly a function of the lack of analysis and research on economic questions – but that picture is changing.